BidaskClub Upgrades NantHealth Inc (NH) to Sell
NantHealth Inc (NYSE:NH) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.
Several other brokerages have also recently issued reports on NH. Jefferies Group LLC reaffirmed a “buy” rating and set a $5.50 target price (down previously from $8.00) on shares of NantHealth in a research report on Monday, June 19th. Canaccord Genuity reaffirmed a “buy” rating and set a $6.00 target price (down previously from $8.00) on shares of NantHealth in a research report on Monday, August 21st. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $8.55.
Shares of NantHealth (NYSE NH) traded up 4.75% during midday trading on Friday, hitting $3.97. The stock had a trading volume of 162,338 shares. The company’s 50 day moving average is $3.60 and its 200 day moving average is $4.13. The firm’s market cap is $484.13 million. NantHealth has a 52 week low of $2.60 and a 52 week high of $15.80.
NantHealth (NYSE:NH) last announced its earnings results on Thursday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.32. The company had revenue of $26.23 million for the quarter, compared to analysts’ expectations of $31.28 million. NantHealth had a negative net margin of 267.11% and a negative return on equity of 83.97%. The firm’s quarterly revenue was down 16.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.15) EPS. On average, equities analysts predict that NantHealth will post ($0.70) earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. TIAA CREF Investment Management LLC boosted its position in NantHealth by 68.6% in the first quarter. TIAA CREF Investment Management LLC now owns 20,200 shares of the company’s stock worth $100,000 after purchasing an additional 8,217 shares during the last quarter. Alliancebernstein L.P. purchased a new position in NantHealth in the second quarter worth $102,000. GSA Capital Partners LLP purchased a new position in NantHealth in the second quarter worth $121,000. Bank of America Corp DE boosted its position in NantHealth by 366.4% in the first quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock worth $125,000 after purchasing an additional 19,694 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in NantHealth by 351.8% in the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock worth $134,000 after purchasing an additional 24,588 shares during the last quarter.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.